Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.078 AUD -2.5% Market Closed
Market Cap: 126.6m AUD

Syntara Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Syntara Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Syntara Ltd
ASX:SNT
Depreciation & Amortization
-AU$234k
CAGR 3-Years
58%
CAGR 5-Years
38%
CAGR 10-Years
27%
Mayne Pharma Group Ltd
ASX:MYX
Depreciation & Amortization
-AU$59.7m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Depreciation & Amortization
-AU$72.6k
CAGR 3-Years
8%
CAGR 5-Years
-114%
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Depreciation & Amortization
-AU$6.2m
CAGR 3-Years
-100%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vita Life Sciences Ltd
ASX:VLS
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Syntara Ltd
Glance View

Market Cap
126.6m AUD
Industry
Pharmaceuticals

Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

SNT Intrinsic Value
0.047 AUD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Syntara Ltd's Depreciation & Amortization?
Depreciation & Amortization
-234k AUD

Based on the financial report for Jun 30, 2024, Syntara Ltd's Depreciation & Amortization amounts to -234k AUD.

What is Syntara Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
27%

Over the last year, the Depreciation & Amortization growth was 87%. The average annual Depreciation & Amortization growth rates for Syntara Ltd have been 58% over the past three years , 38% over the past five years , and 27% over the past ten years .

Back to Top